Valuation: Sarepta Therapeutics, Inc.

Market Cap 2B 1.79B 1.66B 1.5B 2.8B 190B 2.83B 19.79B 7.88B 99.44B 7.49B 7.33B 316B P/E 2026 *
6.35x
P/E 2027 * 82.5x
Enterprise Value 1.75B 1.57B 1.45B 1.32B 2.46B 167B 2.49B 17.37B 6.92B 87.27B 6.57B 6.43B 277B EV / Sales 2026 *
0.96x
EV / Sales 2027 * 1x
Free-Float
94.53%
Yield 2026 *
-
Yield 2027 * -
1 day+1.03%
1 week+2.61%
Current month+4.53%
1 month+1.30%
3 months+23.43%
6 months-9.61%
Current year-11.50%
1 week 17.16
Extreme 17.155
19.21
1 month 16.37
Extreme 16.3675
19.7
Current year 14.68
Extreme 14.68
24.68
1 year 14.68
Extreme 14.68
24.68
3 years 10.42
Extreme 10.415
173.25
5 years 10.42
Extreme 10.415
173.25
10 years 10.42
Extreme 10.415
181.83
Manager TitleAgeSince
Chief Executive Officer 60 28/07/2026
Director of Finance/CFO 47 16/07/2025
Director of Finance/CFO 50 14/12/2020
Director TitleAgeSince
Chairman 73 16/04/2015
Director/Board Member 87 01/06/2010
Director/Board Member 67 02/06/2015
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Tax

Chief Financial Officer

-13,272 0.0126%
04/09/26 Tax

General Counsel

-22,025 0.0209%
04/09/26 Tax

Chairperson

-24,799 0.0235%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%+2.61%-21.37%-82.31% 2B
+0.68%+1.36%+57.06%+127.68% 1,143B
+0.84%+5.37%+45.31%+84.74% 647B
+0.19%+1.01%+26.43%+102.74% 506B
-0.05%+1.73%+52.74%+65.27% 384B
-0.96%-6.29%+61.39%+36.79% 350B
+0.34%+1.84%+30.70%+52.69% 293B
-0.45%+1.19%+2.89%+24.92% 265B
+0.54%+2.89%+54.40%+71.36% 242B
-0.19%+3.79%+35.22%+104.96% 197B
Average +0.18%+0.62%+34.48%+58.88% 402.95B
Weighted average by Cap. +0.25%+0.71%+44.54%+87.00%

Financials

2026 *2027 *
Net sales 1.83B 1.64B 1.52B 1.38B 2.57B 174B 2.6B 18.17B 7.24B 91.31B 6.88B 6.73B 290B 1.38B 1.24B 1.15B 1.04B 1.94B 132B 1.96B 13.69B 5.45B 68.81B 5.18B 5.07B 218B
Net income 340M 305M 282M 255M 477M 32.35B 483M 3.37B 1.34B 16.93B 1.27B 1.25B 53.75B -6.15M -5.51M -5.1M -4.62M -8.63M -585M -8.73M -60.96M -24.28M -306M -23.07M -22.58M -972M
Net Debt -244M -219M -203M -184M -343M -23.27B -347M -2.42B -965M -12.18B -917M -897M -38.65B -618M -554M -512M -464M -867M -58.82B -877M -6.12B -2.44B -30.78B -2.32B -2.27B -97.71B
Projected Income Statement - Annual - Sarepta Therapeutics, Inc.
Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Employees
835
Date Price Change Volume
28/10/26 $19.04 +0.77% 566,488
27/10/26 $18.89 +5.06% 2,226,641
26/10/26 $17.98 +1.41% 1,361,777
23/10/26 $17.73 -2.48% 1,285,459
22/10/26 $18.18 -2.05% 1,235,539
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Sarepta Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
18.89USD
Average target price
21.64USD
Spread / Average Target
+14.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sarepta Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SRPT Stock